Your browser doesn't support javascript.

Biblioteca Virtual en Salud

Hipertensión

Home > Búsqueda > ()
XML
Imprimir Exportar

Formato de exportación:

Exportar

Email
Adicionar mas contactos
| |

Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course

Jonathan Muri; Valentina Cecchinato; Andrea Cavalli; Akanksha A. Shanbhag; Milos Matkovic; Maira Biggiogero; Pier Andrea Maida; Jacques Moritz; Chiara Toscano; Elaheh Ghovehoud; Raffaello Furlan; Franca Barbic; Antonio Voza; Guendalina De Nadai; Carlo Cervia; Yves Zurbuchen; Patrick Taeschler; Lilly A. Murray; Gabriela Danelon-Sargenti; Simone Moro; Tao Gong; Pietro Piffaretti; Filippo Bianchini; Virginia Crivelli; Lucie Podesvova; Mattia Pedotti; David Jarrossay; Jacopo Sgrignani; Sylvia Thelen; Mario Uhr; Enos Bernasconi; Andri Rauch; Antonio Manzo; Adrian Ciurea; Marco Bruno Luigi Rocchi; Luca Varani; Bernhard Moser; Barbara Bottazzi; Marcus Thelen; Brian A. Fallon; Onur Boyman; Alberto Mantovani; Christian Garzoni; Alessandra Franzetti-Pellanda; Mariagrazia Uguccioni; Davide F. Robbiani.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-493121
Infection by SARS-CoV-2 leads to diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse COVID-19 outcomes. Instead, we discovered that antibodies against specific chemokines are omnipresent after COVID-19, associated with favorable disease, and predictive of lack of long COVID symptoms at one year post infection. Anti-chemokine antibodies are present also in HIV-1 infection and autoimmune disorders, but they target different chemokines than those in COVID-19. Monoclonal antibodies derived from COVID- 19 convalescents that bind to the chemokine N-loop impair cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising anti-chemokine antibodies associated with favorable COVID-19 may be beneficial by modulating the inflammatory response and thus bear therapeutic potential. One-Sentence SummaryNaturally arising anti-chemokine antibodies associate with favorable COVID-19 and predict lack of long COVID.